Details

Autor(en) / Beteiligte

• Walz, Simon
• Wang, Qingqing
• Zhao, Xinjie
• Hoene, Miriam
• Häring, Hans-Ulrich
• Hennenlotter, Jörg
• Maas, Moritz
• Peter, Andreas
• Todenhöfer, Tilman
• Stenzl, Arnulf
• Liu, Xinyu
• Lehmann, Rainer
• Xu, Guowang

Titel

Comparison of the metabolome in urine prior and eight weeks after radical prostatectomy uncovers pathologic and molecular features of prostate cancer

Ist Teil von

• Journal of pharmaceutical and biomedical analysis, 2021-10, Vol.205, p.114288-114288, Article 114288

Ort / Verlag

Elsevier B.V

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• •UPLC-MS-based non-targeted metabolomics was applied in prostate cancer study.•Metabolic characteristics of urine in patients pre- and post-radical prostatectomy were assessed for the first time.•A total of 23 metabolites were found altered significantly before and after surgery.•Fatty acid metabolism played an important role in prostate malignancy. Prostate cancer (PCa) is associated with cellular metabolism alterations leading to changes of the metabolome. So far, studies investigating these alterations mainly focused on comparisons of metabolite profiles of PCa patients and healthy controls. In the present study we compared for the first time metabolite profiles in a significant number of paired urine samples collected before and eight weeks after radical prostatectomy (rPX) in 34 patients with PCa. Our comprehensive non-targeted liquid chromatographic-mass spectrometric metabolomics approach covered > 3000 metabolite ion masses. We annotated 23 metabolites showing significant changes eight weeks after rPX. While the levels of uridine and six acylcarnitines in urine were increased before surgery, lower levels were detected for 16 metabolites, like e.g. citrate, phenyl-lactic acid, choline, myo-inositol, emphasizing a relevant pathophysiological role of these biomarkers and the associated metabolic pathways. These results have important implications for potential use of metabolome analyses for detection of prostate cancer and related pathologic and molecular features.